This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks Hedge Funds Love -- and So Should You


Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

When big pharma companies don't want to do the heavy lifting to develop a new drug, they farm the research out to Covance (CVD). The firm provides a range of drug development and laboratory testing services to clients in the pharma, biotech and agrochem industries, digging out a highly profitable niche in the process.

Hedge funds love this stock right now. In the last quarter alone, funds picked up 2.34 million shares of the firm, building their current stake in the firm to $170 million.

>>5 Toxic Stocks You Should Sell in February

Covance offers some big advantages for its clients. Going with a contracted research firm can save time, money, and logistical costs from being borne by pharma firms themselves, instead spreading the huge cost of research facilities across CVD's more active client base during downtime. As big pharma firms increase their marketing and acquisition search efforts (at the expense of R&D), Covance's services help balance incentives a bit better.

The firm's long-term deals with big drugmakers such as Eli Lilly (LLY) and Sanofi (SAN) give it a big moat vs. other third-party research firms because they keep revenues at home. Scale doesn't hurt either; with bigger and better lab facilities than their next closest competitor, CVD is able to take on contracts that smaller research firms can't.

A spotless balance sheet with a big net cash position is a good signal for management's stewardship abilities in 2013. Momentum has been on fire for CVD in 2013. Investors looking for a relative strength play should follow hedge funds into this name.
3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
CVD $106.42 0.00%
YUM $79.56 0.00%
ADT $41.98 0.00%
GM $31.80 0.00%
LOW $76.02 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs